H.C. Wainwright Reiterates Buy Rating on Engene Holdings Inc. (ENGN)

H.C. Wainwright analyst Andres Maldonado reiterated a Buy rating and $25.00 price target on Engene Holdings Inc. (NASDAQ: ENGN).

The analyst commented: "enGene's lead candidate, detalimogene voraplasmid, is currently being evaluated in the pivotal LEGEND study (Cohort 1) for patients with high-risk non-muscle invasive bladder cancer (HR-NMIBC) with carcinoma in situ (CIS) who are unresponsive to Bacillus Calmette-Guérin (BCG). Early data indicate a promising clinical profile, with detalimogene achieving a 71% complete response (CR) at any time and a 47% CR at six months (Kaplan-Meier estimate: 51% at six months). These results compare favorably with recent approvals, where CR rates at any time have ranged from 41% to 62%. enGene is expected to provide an additional interim update from the pivotal cohort in 2H25, followed by a final data readout and Biologics License Application (BLA) submission) in 2026. Reiterate Buy and $25 price target."

For an analyst ratings summary and ratings history on Engene Holdings Inc. click here. For more ratings news on Engene Holdings Inc. click here.

Shares of Engene Holdings Inc. closed at $5.24 yesterday.

You May Also Be Interested In

• Nomura/Instinet Upgrades Genting Singapore (GENS:SP) (GIGNY) to Neutral
• Desjardins Downgrades Alithya Group Inc. (ALYA:CN) (ALYA) to Hold
• Barclays Downgrades HelloFresh SE (HFG:GR) (HLFFF) to Underweight